Expanding Ampyra's Reach? Studies In Other Neurological Conditions Have Stumbled, But Acorda Has Not Ruled Out Future Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The fampridine molecule has been used as a pharmacy compounded product for a variety of neurological conditions based on its mechanism of action. In animal studies, the drug "has been shown to increase conduction of nerve signals in demyelinated axons through blocking of potassium channels," Acorda observed in its annual 10-K filing on Feb. 26.